RELATED STUDY
Key Findings:
Type of Study:
Study Result: Inconclusive
Research Location(s):
Year of Pub:
Cannabinoids Studied:
Chemotype:
Terpenes Studied:
Receptors Studied:
Ligands Studied:
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration:
Cannabinoid Ratio: (THCV) 0 
Dosing Regimen: THCV was administered i.p. at 2 mg/kg
Treatment Duration: 2 weeks
Clinical Relevance: Data suggests a therapeutic potential (anti-dyskinesia) of Δ9-THCV. More specifically, THCV delayed the occurrence and attenuated the magnitude of dyskinesia in an animal model of PD.
Citation:
